Tumour rejection

The potential for tumour formation in patients after treatment with immunosuppressive antibodies must be evaluated. However, the issue is not carcinogenesis per se such antibodies do not cause tumours, they allow nascent tumours to become expressed. Hence, this is a host defence issue which may be addressed using models of tumour rejection. 

The science of immunology not only encompasses the body s immune responses to bacteria and viruses but is extensively involved in tumour recognition and subsequent rejection the rejection of transplanted organs and tissues the elimination of parasites ftom the body allergies and autoimmunity (the condition when the body mounts a reachon agairrst its own tissues). 

Astralagus 2. Echinacea 3. Liquorice 4. Milk thistle 5. Neem 6. Sea buckthorn 1. Ciclosporin 2. Azathioprine 3. Methotrexate 4. Tacrolimus 5. Dadizumab 6. Cyclophosphamide Possibility of graft rejection 1 blood level unknown mechanism (astralagus). Other mechanisms alkyl amides from echinacea modulate tumour necrosis factor alpha mRNA expression in human monocytes/macrophages via the cannabinoid type 2 receptor Unknown mechanism (milk thistle is known to l cyclosporine levels neem L effects of azathioprine, prednisolone and dadizumab sea buckthorn may 1 effect of cyclophosphamide) Induces metabolizing enzymes, CYP3A4 and P-gp (St John s wort L ciclosporin and tacrolimus levels) Avoid concomitant use of the herb... 

M14. Maury, C. P., and Teppo, A. M. Raised serum levels of cachectin/tumour necrosis factor alpha in renal allograft rejection. J. Exp. Med. 166, 1132-1137 (1987). 

Stacker The vessels that are recruited or at least expand in the rejection process have strong expression of markers for lymphatic vessels. It was previously thought there was an infiltration of angiogenic vessels, and this was part of the rejection process. It appears now as though a high proportion of those vessels have lymphatic markers and appear to be behaving as lymphatic vessels. This is only one of a few immune regulated model that has been reasonably studied, apart from the tumour models which have been well characterized. 

In an open-label, multicenter trial, de novo kidney transplant recipients (KTRs) were randomised at week 7 posttransplant to remain on ciclosporin (n = 100, controls) or convert to everolimus (n = 102), both with enteric-coated mycophenolate sodium and corticosteroids. The incidence of oedema, acne, anaemia, mouth ulceration and hypercholesterolaemia was higher in the everolimus arm. Serious adverse events or infections that occurred in more than two everolimus-treated patients comprised pneumonia, lymphocele, increased plasma creatinine, sepsis, gastroenteritis, cytomegalovirus (CMV) infection, rejection and hydronephrosis. Two malignant neoplasms occurred in each group (everolimus malignant parathyroid tumour, adenocarcinoma of the prostate) [ll -]. 

---